- Ajinomoto Bio-Pharma Services and Olon S.p.A. have entered a strategic partnership to advance large-scale biologics manufacturing, combining microbial process development and GMP fermentation expertise.
- The collaboration aims to enhance production of peptides and proteins, including GLP-1 analogs for obesity and diabetes, with a focus on sustainability and scalability.
Ajinomoto Bio-Pharma Services (Aji Bio-Pharma) and Olon S.p.A. have announced a strategic partnership to expand global biopharmaceutical manufacturing capacity through the integration of microbial technologies and large-scale fermentation capabilities.
The collaboration combines Aji Bio-Pharma’s microbial CORYNEX® platform—designed for peptide and protein manufacturing—with Olon’s large-scale microbial fermentation infrastructure, which includes fermenters exceeding 100,000 litres in capacity. The partnership will focus on producing high-demand biologics such as GLP-1 analogues used in obesity and type II diabetes treatments.
“By joining forces, we can accelerate the development and supply of advanced peptides and proteins, supporting our customers and improving patient outcomes in a sustainable manner.”
Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Department, Ajinomoto Co., Inc.
Andrea Conforto, S&M – VP CDMO Biotech, Olon S.p.A., added that the alliance “provides a seamless path from development to large-scale commercial manufacturing.”
Both companies emphasised that sustainability is central to their collaboration, combining environmentally responsible production methods with scalable fermentation technologies to reduce the environmental footprint of biologics manufacturing.
Aji Bio-Pharma’s CORYNEX® platform uses C. glutamicum, a gram-positive bacterium that secretes biologically active proteins directly into the media, simplifying purification and improving efficiency. Olon contributes deep microbial fermentation experience and a total capacity of 5,000 m³ across Europe.
